Library Item - Page 38 of 792 Posts on Medivizor
Navigation Menu

Library Item Posts on Medivizor

Evaluating the real-world safety and effectiveness of palbociclib and hormonal therapy in patients with advanced breast cancer.

Evaluating the real-world safety and effectiveness of palbociclib and hormonal therapy in patients with advanced breast cancer.

Posted by on Nov 27, 2021 in Breast cancer | 0 comments

In a nutshell This study investigated whether the combination of hormonal therapy and cyclin-dependent kinase (CDK) 4/6 inhibitor palbociclib (Ibrance) was effective in advanced breast cancer in a real-world practice. The authors found that this treatment has similar safety and effectiveness in these patients as shown in clinical trials. Also,...

Read More

Evaluating the effectiveness of T-VEC after failure of immunotherapy in patients with unresectable metastatic melanoma.

Evaluating the effectiveness of T-VEC after failure of immunotherapy in patients with unresectable metastatic melanoma.

Posted by on Nov 27, 2021 in Melanoma | 0 comments

In a nutshell This study evaluated the effectiveness of talimogene laherparepvec (Imlygic; T-VEC) after failure of immunotherapy for the treatment of patients with unresectable metastatic melanoma. The data showed that T-VEC after the failure of immunotherapy is safe and effective in these patients. Some background Melanoma is an aggressive type of...

Read More

How safe and effective is epcoritamab for the treatment of patients with relapsed or refractory B-cell non-Hodgkin lymphoma?

How safe and effective is epcoritamab for the treatment of patients with relapsed or refractory B-cell non-Hodgkin lymphoma?

Posted by on Nov 21, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The authors investigated the safety and effectiveness of epcoritamab (DuoBody-CD3xCD20) for the treatment of patients with relapsed or refractory (r/r) CD20+ B-cell non-Hodgkin lymphoma (B-NHL). The study showed that this medication has promising effectiveness and safety in these patients.  Some background B-NHL is a type of...

Read More

Daratumumab maintenance therapy after autologous stem-cell transplant in patients with newly diagnosed multiple myeloma.

Daratumumab maintenance therapy after autologous stem-cell transplant in patients with newly diagnosed multiple myeloma.

Posted by on Nov 21, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study investigated the use of daratumumab (Darzalex) as maintenance therapy following autologous stem-cell transplant (ASCT) in patients with newly diagnosed multiple myeloma (NDMM). The data showed that maintenance therapy with daratumumab resulted in significant improvements in outcomes compared to observation only in patients that...

Read More

Reviewing the changes in quality of life and lower urinary tract symptoms in patients with prostate cancer following prostate surgery

Reviewing the changes in quality of life and lower urinary tract symptoms in patients with prostate cancer following prostate surgery

Posted by on Nov 14, 2021 in Prostate cancer | 0 comments

In a nutshell This review explained the changes in lower urinary tract symptoms (LUTS) and quality of life (QoL) that occurred over time in patients with prostate cancer following radical prostatectomy (RP; removal of the prostate). The data showed that 6 to 12 months are required for LUTS improvement after RT. Some background Patients with prostate...

Read More

Preparing the uterus for frozen embryo transfer

Preparing the uterus for frozen embryo transfer

Posted by on Nov 14, 2021 in Infertility | 0 comments

In a nutshell This study compared two medication protocols to prepare the uterus for frozen embryo transfer (FET). It found that down-regulation ovulation-induction (DROI) led to higher pregnancy rates than a modified natural cycle (mNC). Some background In vitro fertilization (IVF) is an infertility technique in which eggs are collected and...

Read More

Is radiotherapy useful for the treatment of advanced Hodgkin lymphoma with bulky sites previously exposed to ABVD?

Is radiotherapy useful for the treatment of advanced Hodgkin lymphoma with bulky sites previously exposed to ABVD?

Posted by on Nov 14, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated the potential benefits of radiotherapy (RT) for the treatment of patients with advanced-stage Hodgkin lymphoma (HL) who have achieved a complete metabolic response (CMR) after ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine)-based chemotherapy. The data showed no significant difference in patient outcomes...

Read More

Evaluating the use of very low dose radiation treatment for painless non-Hodgkin lymphoma

Evaluating the use of very low dose radiation treatment for painless non-Hodgkin lymphoma

Posted by on Nov 14, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The study aimed to investigate if very low-dose radiotherapy (VLDRT) was effective in treating patients with indolent (painless) non-Hodgkin lymphoma (NHL).   This study concluded that this treatment can be effective in these patients.   Some background Radiotherapy (RT) is an important treatment in managing patients...

Read More

Evaluating infection risk in patients with blood cancers treated with new targeted therapy drugs

Evaluating infection risk in patients with blood cancers treated with new targeted therapy drugs

Posted by on Nov 14, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to investigate the risk of infections in patients with blood cancers who were treated with new biological therapy drugs.  This study concluded that a high proportion of these patients experienced severe infections. However, the infection risk was similar to that of chemotherapy.   Some background...

Read More

Evaluating infection risk in patients with blood cancers treated with new targeted therapy drugs

Evaluating infection risk in patients with blood cancers treated with new targeted therapy drugs

Posted by on Nov 14, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to investigate the risk of infections in patients with blood cancers who were treated with new biological drugs.  This study concluded that a high proportion of these patients experienced severe infections. However, the infection risk was similar to that of chemotherapy.  Some background Treatments for...

Read More

Evaluating infection risk in patients with blood cancers treated with new targeted therapy drugs

Evaluating infection risk in patients with blood cancers treated with new targeted therapy drugs

Posted by on Nov 14, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the risk of infections in patients with blood cancers who were treated with new targeted therapy drugs.  This study concluded that a high proportion of these patients experienced severe infections. However, the infection risk was similar to that of chemotherapy.  Some background Treatments for...

Read More